Treating oligodendroglioma - An analysis of a homogeneous 1p/19q-codeleted and isocitrate dehydrogenase-mutant patient cohort.

ABSTRACT:

Background

Oligodendrogliomas (ODG) are rare, diffusely infiltrating brain tumors, defined by their 1p/19q-codeletion and isocitrate dehydrogenase (IDH) mutation. Herein, we analyze the influence of various tumor and patient characteristics on progression-free survival (PFS) and overall survival (OS) in a homogeneous patient cohort.

Material and methods

Patients treated for a 1p/19q-codeleted and IDH-mutant ODG were evaluated. The patient and tumor characteristics were analyzed for their influence on PFS and OS.

Results

One-hundred-fourteen patients met the inclusion criteria. The median clinical and radiographic follow-up periods were 68.6 and 69.8 months. The median PFS and OS were 66.9 and 236.0 months, respectively. The 2-, 4- and 6-year PFS rates were 89.5%, 76.3

SUBMITTER: Allwohn L 

PROVIDER: S-EPMC10192391 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature